androsta-5,16-dien-3α-ol | 30505-67-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: androsta-5,16-dien-3α-ol
• 英文别名: 5α-5,16-Androstadien-3α-ol；Androsta-5,16-dien-3alpha-ol；(3R,8S,9S,10R,13R,14S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 30505-67-0
• 化学式: C₁₉H₂₈O
• 分子量: 272.431
• InChiKey: QVHPTAJAHUONLV-UGCZWRCOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  androsta-5,16-dien-3α-ol 在 全氟丁基磺酰氟 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以61%的产率得到3β-fluoro-androsta-5,16-diene
  参考文献：
  名称：

  PREPARATION OF 3α-FLUORO- AND 3β-FLUORO DERIVATIVES OF 5α-ANDROST-16-ENES AND ANDROSTA-5,16-DIENES

  摘要：

  n-Perfluorobutanesulfonyl fluoride, in the presence of DBU, is shown to be a convenient and satisfactory reagent for the preparation of a variety of unsaturated 3-fluorosteroids of defined stereochemistry. 3-Fluoro-16,17-dehydrosteroids are reported for the first time. Fluorodehydroxylation proceeded with retention of configuration for 5,6,16,17-tetradehydro-3beta-sterols, but with inversion for their 3alpha-analogues, as it did for several 16,17-dehydrosterols.

  DOI：

  10.1081/scc-120005419
• 作为产物：
  描述：

  (3S,8S,9S,10R,13R,14S)-10,13-二甲基-2,3,4,7,8,9,11,12,14,15-十氢-1H-环戊并[a]菲-3-醇 生成 androsta-5,16-dien-3α-ol
  参考文献：
  名称：

  类固醇感官过程的结构和构型依赖性†

  摘要：

  睾丸激素和19-去甲睾丸激素的结构修饰已导致合成了60多种雄甾烷和雌二醇衍生物，其感官评估已为释放“类固醇型”气味建立了分子参数。两种类别的含O化合物的气味感知都具有区域选择性1。C（3）处的渗透基团是最活跃和最特异的。C（2）处的功能在很大程度上伴随着原子缺陷，并且在特殊情况下，C（1）和C（4）处的含O取代基似乎会影响受体膜。

  DOI：

  10.1002/hlca.19830660121

文献信息

• 5<i>α</i>-Androst-16-en-3<i>α</i>-ol<i>β</i>-<scp>D</scp>-Glucuronide, Precursor of 5<i>α</i>-Androst-16-en-3<i>α</i>-ol in Human Sweat
  作者：Christian Starkenmann、Fabienne Mayenzet、Robert Brauchli、Myriam Troccaz

  DOI：10.1002/cbdv.201300286

  日期：2013.12

  5α-Androst-16-en-3α-ol (α-androstenol) is an important contributor to human axilla sweat odor. It is assumed that α-andostenol is excreted from the apocrine glands via a H2 O-soluble conjugate, and this precursor was formally characterized in this study for the first time in human sweat. The possible H2 O-soluble precursors, sulfate and glucuronide derivatives, were synthesized as analytical standards

  5α-Androst-16-en-3α-ol（α-androstenol）是造成人腋臭的重要因素。假定α-雄烯醇通过可溶于H2 O的结合物从顶泌腺中排出，并且该前体在本研究中首次在人类汗液中正式表征。合成了可能的H2 O可溶性前体硫酸盐和葡糖醛酸衍生物，作为分析标准品，即α-雄烯醇，β-雄烯醇硫酸盐，5α-雄烯醇-5,16-dien-3β-醇（β-雄甾烷醇）， α-雄甾烯醇β-葡糖醛酸，α-雄甾烯醇α-葡糖醛酸，β-雄甾烷二烯醇β-葡糖醛酸和α-雄甾烯醇β-葡糖醛酸呋喃糖。通过超高效液相色谱法（UPLC）/ MS（加热电喷雾电离（HESI））以负离子模式在合并的人类汗液中建立了α-雄甾烯醇β-葡萄糖醛酸的存在，含有内分泌和外分泌分泌物，并从25名女性和24名男性腋下收集。其浓度在雌性分泌物中为79 ng / ml，在雄性分泌物中为241 ng / ml。在将无菌人类汗液或α-雄烯醇β-葡萄
• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• Novel androstanes for inducing hypothalamic effects
  申请人：——

  公开号：US20020103391A1

  公开（公告）日：2002-08-01

  The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.

  该发明涉及一种新型的雄甾烷类固醇，它们是与神经上皮受体结合的配体信号化学物质。
• Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
  申请人：——

  公开号：US20020143001A1

  公开（公告）日：2002-10-03

  The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

  本发明涉及一种改变个体下丘脑功能的方法。该方法包括经鼻给予人类信息素，例如Androstane类固醇或含有信息素的药物组合物，使配体信息素与特定神经上皮受体结合。该类固醇通常以含有一种或多种药用载体的药物组合物的形式给予。本发明的其他实施方式包括含有该类固醇的药物组合物。
• Fragrance compositions and other compositions which contain human pheromones
  申请人：EROX CORPORATION

  公开号：EP0562843A2

  公开（公告）日：1993-09-29

  The invention concerns novel, non-therapeutic fragrance compositions and other compositions containing an odorant and a naturally occurring human pheromone. The invention also concerns fragrance compositions containing mixtures of naturally occurring human pheromones. The human pheromones disclosed are steroids which desirably belong to two distinct chemical classes: 16-Androstenes and Estrenes.

  本发明涉及新颖的非治疗性香料组合物和其他含有臭味剂和天然人类信息素的组合物。本发明还涉及含有天然人类信息素混合物的香料组合物。本发明公开的人类信息素是类固醇，它们最好属于两个不同的化学类别：16-雄烯类和雌烯类。